SCHEMBL9101974

SCHEMBL9101974

Cc1cc(NC(=O)c2ncccc2OCC2CCCN2C(=O)C2CCC(C(F)(F)F)CC2)on1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 2/20 0.37
CHRNA3 P32297 2/20 0.37
CHRNB1 P11230 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
CHRNB3 Q05901 1/20 0.37
SMO Q99835 1/20 0.36
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
GRM5 P41594 1/20 0.35
HCRTR1 O43613 1/20 0.35
GABRA1 P14867 1/20 0.34
GPR6 P46095 1/20 0.34
PRKCA P17252 1/20 0.34
PRKCQ Q04759 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GLA P06280 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ATF1 P18846 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9101968 1.00 CHRNB4 (0.37) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL1238434 0.89 TSHR (0.39) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL1238437 0.89 TSHR (0.39) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL1238435 0.89 TSHR (0.39) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL1241463 0.88 CHRNB4 (0.36) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL1241461 0.88 CHRNB4 (0.36) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL1241465 0.88 CHRNB4 (0.36) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL9100188 0.87 CHRNB4 (0.37) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL9100184 0.87 CHRNB4 (0.37) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4
SCHEMBL1241272 0.84 ELANE (0.40) CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969383-B2 Picolinamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140296237-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2014-10-02 US disclosed
US-8809380-B2 Picolinamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2014-08-19 US disclosed
US-20120142691-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142691-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS CACNA1G, SCN3A, SCN5A CHRNB4 383/4885CHRNA3 231/4885CHRNB1 654/4885
US-20140296237-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS CACNA1G, SCN3A, SCN5A CHRNB4 383/4885CHRNA3 231/4885CHRNB1 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.